ArticlePloS one2022

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.

Kumiko Koyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.